Recombinant Human CCL25/TECK Protein

Carrier Free

Catalog # Availability Size / Price Qty
9046-TK-025/CF

With Carrier

Catalog # Availability Size / Price Qty
9046-TK-025
Recombinant Human CCL25/TECK Protein Bioactivity
1 Image
Product Details
Citations (3)
FAQs
Reviews

Recombinant Human CCL25/TECK Protein Summary

Product Specifications

Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Measured by its ability to chemoattract BaF3 mouse pro‑B cells transfected with human CCR9. The ED50 for this effect is 30-180 ng/mL.
Source
E. coli-derived human CCL25/TECK protein
Gln24-Leu150
Accession #
N-terminal Sequence
Analysis
Gln24
Predicted Molecular Mass
14 kDa
SDS-PAGE
14 kDa, reducing conditions

Product Datasheets

You must select a language.

x

9046-TK (with carrier)

You must select a language.

x

9046-TK/CF (carrier free)

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

9046-TK

Formulation Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA with BSA as a carrier protein.
Reconstitution Reconstitute at 250 μg/mL in 4 mM HCl.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

9046-TK/CF

Formulation Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA.
Reconstitution Reconstitute at 250 μg/mL in 4 mM HCl.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

Bioactivity Recombinant Human CCL25/TECK Protein Bioactivity View Larger

Recombinant Human CCL25/TECK (Catalog # 9046-TK) chemoattracts the BaF3 pro-B cells transfected with human CCR9. The ED50 for this effect is 30-180 ng/mL.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: CCL25/TECK

CCL25, also known as TECK (thymus-expressed chemokine), is a CC chemokine that regulates the trafficking of lymphocytes in the thymus and small intestine. Mature human CCL25 shares 40% amino acid sequence identity with mouse and rat CCL25 (1). CCL25 is produced by stromal cells in the thymus and epithelial cells of the small intestine, particularly the jejunum and ileum (1-3). It binds to and induces chemoattraction through CCR9 (1, 4, 5), and both human and mouse proteins act on human CCR9 (4). CCR9 is expressed on immature pre-T cells and thymocytes (5, 6). CCL25 induces the homing of several lymphocyte populations to the small intestine (3), including Integrin alpha 4 beta 7+ gamma δ T cells (6, 7), Integrin alpha E beta 7+ CD8+ T cells (8), and IgA-producing plasma cells (2). In cancer, functional CCR9 mediates the metastasis of melanoma cells to the small intestine (9), contributes to the CCL25-dependent migration and invasion of some breast carcinomas (10), and attracts mesenchymal stromal cells to CCL25-expressing multiple myelomas (11). CCL25 contributes to the severity of chronic inflammation in rheumatoid arthritis where it attracts CCR9+ monocytes and macrophages (12), in endometriosis where it promotes the invasiveness of stromal cells (13), and in atherosclerosis where it contributes to the accumulation of CCR9+ macrophages in arterial plaques (14).

References
  1. Vicari, A.P. et al. (1997) Immunity 7:291.
  2. Bowman, E.P. et al. (2002) J. Exp. Med. 195:269.
  3. Kunkel, E.J. et al. (2000) J. Exp. Med. 192:761.
  4. Zaballos, A. et al. (1999) J. Immunol. 162:5671.
  5. Youn, B.-S. et al. (1999) Blood 94:2533.
  6. Uehara, S. et al. (2002) J. Immunol. 168:134.
  7. Costa, M.F.S. et al. (2012) Eur. J. Immunol. 42:1250.
  8. Svensson, M. et al. (2002) J. Clin. Invest. 110:1113.
  9. Amersi, F.F. et al. (2008) Clin. Cancer Res. 14:638.
  10. Johnson-Holiday, C. et al. (2011) Int. J. Oncol. 38:1279.
  11. Xu, S. et al. (2012) Stem Cells 30:266.
  12. Schmutz, C. et al. (2010) Arthritis Res. Ther. 12:R161.
  13. Wang, Y. et al. (2010) Cell. Mol. Immunol. 7:51.
  14. Alla, J.A. et al. (2010) J. Biol. Chem. 285:23496.
Entrez Gene IDs
6370 (Human); 20300 (Mouse)
Alternate Names
C-C motif chemokine 25; CCL25; chemokine (C-C motif) ligand 25; Chemokine TECK; Ck beta-15; Ckb15; SCYA25TECKvar; small inducible cytokine subfamily A (Cys-Cys), member 25; Small-inducible cytokine A25; TECK; TECKMGC150327; thymus expressed chemokine; Thymus-expressed chemokine

Citations for Recombinant Human CCL25/TECK Protein

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

3 Citations: Showing 1 - 3
Filter your results:

Filter by:

  1. CCL25/CCR9 interaction promotes the malignant behavior of salivary adenoid cystic carcinoma via the PI3K/AKT signaling pathway
    Authors: S Chai, Z Wen, R Zhang, Y Bai, J Liu, J Li, W Kongling, W Chen, F Wang, L Gao
    PeerJ, 2022-08-19;10(0):e13844.
    Species: Human, Mouse
    Sample Types: In Vivo, Whole Cells
    Applications: Bioassay
  2. A mutation that blocks integrin alpha4beta7 activation prevents adaptive immune-mediated colitis without increasing susceptibility to innate colitis
    Authors: H Zhang, Y Zheng, Y Pan, C Lin, S Wang, Z Yan, L Lu, G Ge, J Li, YA Zeng, J Chen
    BMC Biol., 2020-06-10;18(1):64.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  3. RAR?/RXR Synergism Potentiates Retinoid Responsiveness in Cutaneous T Cell Lymphoma Cell Lines
    Authors: L Wang, SS DeMarco, MS Peaks, AL Maiorana-B, J Chen, MJ Crouch, BM Shewchuk, SR Shaikh, CM Phillips, LC Bridges
    Exp. Dermatol., 2017-07-03;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs

Reviews for Recombinant Human CCL25/TECK Protein

There are currently no reviews for this product. Be the first to review Recombinant Human CCL25/TECK Protein and earn rewards!

Have you used Recombinant Human CCL25/TECK Protein?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review